NASDAQ:STAA - STAAR Surgical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$41.14 +0.60 (+1.48 %)
(As of 10/15/2018 06:00 AM ET)
Previous Close$41.14
Today's Range$40.40 - $42.9048
52-Week Range$12.30 - $54.00
Volume362,475 shs
Average Volume368,243 shs
Market Capitalization$2.11 billion
P/E Ratio4,114.00
Dividend YieldN/A
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies


Debt-to-Equity Ratio0.02
Current Ratio2.68
Quick Ratio2.11


Trailing P/E Ratio4,114.00
Forward P/E Ratio1,371.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.61 million
Price / Sales19.95
Cash Flow$0.0783 per share
Price / Cash525.08
Book Value$1.04 per share
Price / Book39.56


EPS (Most Recent Fiscal Year)$0.01
Net Income$-2,130,000.00
Net Margins3.15%
Return on Equity16.04%
Return on Assets9.60%


Outstanding Shares43,940,000
Market Cap$2.11 billion

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) released its quarterly earnings results on Wednesday, August, 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.01 by $0.08. The medical instruments supplier earned $33.91 million during the quarter, compared to analysts' expectations of $27.10 million. STAAR Surgical had a return on equity of 16.04% and a net margin of 3.15%. View STAAR Surgical's Earnings History.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for STAAR Surgical.

What price target have analysts set for STAA?

4 brokers have issued 1-year target prices for STAAR Surgical's stock. Their predictions range from $21.00 to $55.00. On average, they anticipate STAAR Surgical's share price to reach $43.3333 in the next year. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for STAAR Surgical.

What is the consensus analysts' recommendation for STAAR Surgical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

What are Wall Street analysts saying about STAAR Surgical stock?

Here are some recent quotes from research analysts about STAAR Surgical stock:
  • 1. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (8/9/2018)
  • 2. Canaccord Genuity analysts commented, "We view the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the US market now fully accessible to STAA. While the near term now looks even brighter, we think the firm’s longer-term potential, both with presbyopia (a ~1.5M-patient annual TAM by company estimates) and with full entry into the US market (the second-largest refractive market in the world) acting as major growth drivers – drivers we expect to support sustained, double- digit organic growth into the next decade and beyond. We reiterate our BUY rating and increase our price target to $32 (9.1x EV/sales on 2020E)." (6/20/2018)

Are investors shorting STAAR Surgical?

STAAR Surgical saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,173,056 shares, an increase of 36.8% from the August 15th total of 857,551 shares. Based on an average trading volume of 435,777 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.8% of the company's stock are sold short. View STAAR Surgical's Current Options Chain.

Who are some of STAAR Surgical's key competitors?

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the folowing people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 64)
  • Ms. Deborah Andrews, Chief Financial Officer (Age 61)
  • Dr. Keith Holliday, Chief Technology Officer (Age 55)
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 56)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations - Europe & China (Age 53)

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $41.14.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $2.11 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]

MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel